Study of three drugs for advanced endometrial cancer with RAS mutations
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of three targeted drugs (avutometinib, defactinib, and everolimus) for people whose endometrial cancer has a specific change in the RAS pathway and has not responded to other treatments. The goal is to see if this drug combo can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have endometrial cancer that has come back or spread, and it has a mutation in the RAS pathway (such as KRAS, NRAS, or BRAF).
- You have already tried an immunotherapy drug (like a checkpoint inhibitor) in the past.
- You are able to do your daily activities with little to no help (ECOG score 0 or 1).
- You are at least 18 years old.
- You have tumors that can be measured on scans.
- Your heart, kidneys, and liver are working well enough based on blood tests and a heart ultrasound.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to standard anti-EGFR treatments. The goal is to see if this combination can shrink tumors or slow the cancer down.
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests a combination of two oral targeted drugs for people with recurrent low-grade serous ovarian cancer. It aims to see if this therapy works better than standard hormone therapy or chemotherapy options.
This trial tests a new combination of two targeted therapy drugs (avutometinib and defactinib) plus standard chemotherapy (mFOLFIRINOX) given before any other treatment for pancreatic cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes for patients with advanced pancreatic cancer.
Hear when a new Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.